
Bevacizumab Significantly Improves Survival for Patients With Advanced Cervical Cancer
Patients with advanced cervical cancer who received the drug bevacizumab (Avastin) lived a median 3.7 months longer than patients who did not receive the drug, according to interim results from a large, randomized clinical trial.
• | NCI press release: bevacizumab and cervical cancer |
• | Cervical Cancer home page |
• | Bevacizumab information summary |
Cancer Research News
- Deep genomic analysis identifies a micro RNA opponent for ovarian cancer
- Values and techniques shape decisions about PSA screening
- Mouse model of clear cell sarcoma improves understanding of rare, deadly cancer
Visit the NCI News Center